BMP9 has been suggested as a possible therapeutic strategy for PAH based on the hypothesis that supplementation of exogenous BMP9 could enhance endothelial BMPR2 signaling and reverse PAH in in vivo models (Long et al. 2015). This evidence concerns the gene GDF2 and pulmonary arterial hypertension.